[Neuroborreliosis - Diagnostics, treatment and course].
Lyme neuroborreliosis is a tick-borne infectious disease caused by the spirochete bacterium Borrelia burgdorferi sensu lato. Clinical manifestations are classified as early and late Lyme neuroborreliosis. Early manifestations are much more common than late manifestations. Serological testing should only be performed when typical neurological symptoms are present because false positive results are common due to a high seroprevalence in the population. Cerebrospinal fluid (CSF) analysis should be performed if Lyme neuroborreliosis is suspected. A systematic review found similar effects of beta-lactam antibiotics and doxycycline regarding the outcome of neurological symptoms and adverse effects. The prognosis after antibiotic treatment is usually favorable and residual symptoms can rarely persist. Impairments in quality of life, fatigue, depression and cognitive impairment are not more frequent in patients after treatment of Lyme neuroborreliosis than in the normal healthy population.
Abteilung für Neurologie und Neurophysiologie, Universitätsklinikum Freiburg, Breisacher Str. 64, 79106, Freiburg, Deutschland. rick.dersch@uniklinik-freiburg.de.
R
R
Dersch
Abteilung für Neurologie und Neurophysiologie, Universitätsklinikum Freiburg, Breisacher Str. 64, 79106, Freiburg, Deutschland.
S
S
Rauer
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001898:Borrelia / Q000187:drug effects / Q000302:isolation & purification*; D002555:Cerebrospinal Fluid / Q000382:microbiology*; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D004318:Doxycycline / Q000008:administration & dosage*; D019317:Evidence-Based Medicine; D006801:Humans; D020852:Lyme Neuroborreliosis / Q000175:diagnosis* / Q000382:microbiology / Q000628:therapy*; D016896:Treatment Outcome; D047090:beta-Lactams / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D004318:Doxycycline
Evidence-based medicine; Lyme disease; Lyme neuroborreliosis; Quality of life; Treatment